

Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims

Claims 1-24, 26-29, 31-44 and 49-56 (canceled)

25. (original) A method for treating or preventing a disorder alleviated by inhibiting dopamine reuptake, wherein the disorder is an addictive disorder, comprising administering to a patient in need of such treatment or prevention an effective amount of (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, each being substantially free of its corresponding (+)-enantiomer.

30. (original) The method according to claim 25, wherein the addictive disorder is selected from the group consisting of eating disorders, impulse control disorders, alcohol-related disorders, nicotine-related disorders, amphetamine-related disorders, cannabis-related disorders, cocaine-related disorders, hallucinogen-use disorders, inhalant-related disorders, and opioid-related disorders.

45. (original) A method for treating or preventing an addictive disorder, comprising administering to a patient in need of such treatment or prevention an effective amount of (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, each being substantially free of its corresponding (+)-enantiomer.

46. (original) The method according to claim 45, wherein the (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof has no more than about 2% w/w of the corresponding (+)-enantiomer.

47. (original) The method according to claim 45, wherein the (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof has no more than about 1% w/w of the corresponding (+)-enantiomer.

48. (original) The method according to claim 45, wherein the addictive disorder is selected from the group consisting of eating disorders, impulse control disorders, alcohol related disorders, nicotine-related disorders, amphetamine-related disorders, cannabis-related

disorders, cocaine-related disorders, hallucinogen-use disorders, inhalant-related disorders, and opioid-related disorders.